Novavax Inc. (NVAX) on Wednesday said that the postmarketing commitment study for its COVID-19 vaccine Nuvaxovid will not ...

Novavax NVAX reported second-quarter 2025 earnings per share (EPS) of 62 cents against the Zacks Consensus Estimate of a loss ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Novavax beats Q2 expectations with $239 million in revenue, lifts 2025 guidance, and reports profit as costs decline and ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of India and Japan's Takeda , sending its ...

In Europe, Nuvaxovid sales shot up to $90.4 million during the first quarter, which is already high enough to justify the present valuation of Novavax stock. Sanofi expects to begin recording ...

The agreement also features a non-exclusive license to Novavax's adjuvant technology for Sanofi's non-flu vaccines. Finally, Sanofi made a $70 million investment and acquired a 4.9% stake in Novavax.

Nuvaxovid™ is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S.Biologics License Application approval triggers $175 million Sanofi milestone payment, with ...